Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hae‐Sim Park
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
P2Y12 Antagonist Attenuates Eosinophilic Inflammation and Airway Hyperresponsiveness in a Mouse Model of Asthma
Journal of Cellular and Molecular Medicine
Molecular Medicine
Cell Biology
Related publications
Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Benralizumab for the Treatment of Severe Eosinophilic Asthma
Prescriber
Pharmacology
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Clinical Pharmacology and Therapeutics
Pharmacology
Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma
Annals of Allergy, Asthma and Immunology
Respiratory Medicine
Pulmonary
Allergy
Immunology
Dupilumab Efficacy and Safety in Moderate-To-Severe Uncontrolled AsthmaEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Pediatrics
Child Health
Pediatrics
Perinatology
Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma
Prescriber
Pharmacology
Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma
Pulmonologiya
Pulmonary
Respiratory Medicine
Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study
Clinical Therapeutics
Pharmacology
